LATEST NEWS

November, 2012

Results of Annual General Meeting

Change of Director’s Interest Notice: Washer

Change of Director’s Interest Notice: Dantzker

Change of Director’s Interest Notice: Korten

Change of Director’s Interest Notice: Haghighat

Change of Director’s Interest Notice: MacDonald

October, 2012

iSonea Q1 Report 2013

ISN ASX Confirm Rights Issue Shortfall

Notice of Annual General Meeting and Explanatory Memorandum

Dispatch of Renounceable Pro-Rate Rights Issue Prospectus

iSonea Files FDA Submission for Over-the-Counter SonoSentry™

September, 2012

2012 Annual Report

Letter to Eligible Shareholders on Rights Issue

Letter to Ineligible Shareholders on Rights Issue

iSonea Announces Fully Underwritten Renounceable Rights Issue to Raise $4M

Appendix 3B: application for quotation of additional securities and agreement

Prospectus: Offer to Eligible Shareholders

Letter to Option Holders

iSonea App Now Free

 

 

 

Investor Relations News

November, 2012

Results of Annual General Meeting

Change of Director’s Interest Notice: Washer

Change of Director’s Interest Notice: Dantzker

Change of Director’s Interest Notice: Korten

Change of Director’s Interest Notice: Haghighat

Change of Director’s Interest Notice: MacDonald

October, 2012

iSonea Q1 Report 2013

ISN ASX Confirm Rights Issue Shortfall

Notice of Annual General Meeting and Explanatory Memorandum

Dispatch of Renounceable Pro-Rate Rights Issue Prospectus

iSonea Files FDA Submission for Over-the-Counter SonoSentry™

September, 2012

2012 Annual Report

Letter to Eligible Shareholders on Rights Issue

Letter to Ineligible Shareholders on Rights Issue

iSonea Announces Fully Underwritten Renounceable Rights Issue to Raise $4M

Appendix 3B: application for quotation of additional securities and agreement

Prospectus: Offer to Eligible Shareholders

Letter to Option Holders

iSonea App Now Free

August, 2012

Preliminary Final Report

Notice of Initial Substantial Holder

Bruce Mathieson Becomes Cornerstone Investor of iSonea

Application for Quotation of Additional Securities and Agreement

Change of Director’s Interest Notice, Washer

Change of Director’s Interest Notice, Haghighat

Change of Director’s Interest Notice, Dantzker

Change of Director’s Interest Notice, Korten

Change of Director’s Interest Notice, Washer

iSonea Completes Capital Consolidation

Isonea run successful App trial in Memphis

iSonea Launches Updated AsthmaSense™ Smartphone App for Global Market

Change of Director’s Interest Notice

iSonea Fourth Quarter Results

iSonea Trading Policy

July, 2012

iSonea Announces Results of General Meeting

General Meeting Presentation by Micheal Thomas: Value Appreciation Via Sound Asthma Management

iSonea Announces New Chairman of the Board

June, 2012

Updated Capital Consolidation Timetable

Letter to Shareholders

Sharholder Meeting

OzEquities Analyst Report: Isonea Has Market Leading Asthma Monitoring Products ...

iSonea Launches First Mobile Asthma Technology

April, 2012

Investor Update and Quarterly Report – 31st March 2012

iSonea Announces Changes to Board of Directors

March, 2012

iSonea Launches Pediatric Asthma Study

iSonea Adds Dr. David Dantzker to Board of Directors

iSonea Looks to turn a Smartphone into a Breathing Monitor

iSonea's tech is Covered for Accoustic Monitoring

Cambride Consultants Demos Asthma Training Device

iSonea Issued US Patent for Cough Detector to Diagnose Respiratory Conditions

Dr. Lynn M. Taussig Named Chairman of iSonea’s Medical Advisory Board

February, 2012

iSonea and Qualcomm Life Collaborate on Asthma Mobile Health Technology

Proactiveinvestors News: iSonea rapidly approaches commercialisation, targets US$16 billion asthma market

CEO Shareholder Update and Q2 FY2012 Results

January, 2012

iSonea to present at Cappello Capital Corp Investor Conference

New Issue Announcement, Application for Quotation of Additional Securities and Agreement

iSonea Limited Commences Trading on the U.S. OTCQX International

iSonea Limited Announces Publication of Initial Viriathus Research Report

December, 2011

iSonea receives Subscriptions under Rights Issue...

Shareholders Top 20 Listing

Notice of change of interests of substantial holder (RB)

Appendix 3Y: Change of Director’s Interest Notice (RH)

Notice of ceasing to be a substantial holder

Appendix 3Y: Change of Director’s Interest Notice (JK)

Notice Under Section 708A(5) of the Corporations Act

Appendix 3B: New Issue Announcement, Application for Quotation of Additional Securities and Agreement

Dispatch of Renounceable Pro-Rata Rights Issue Closure, Acceptances, Shortfall

Michael Thomas, iSonea CEO talks with BRR on launch of new iPhone Application

Rights Issue Prospectus Announcement

Value Appreciation Via Sound Asthma Management - December Presentation 2011

Dispatch of Renounceable Pro-Rata Rights Issue Prospectus

iSonea to Commence Trading in US on OTC Exchange 2 January 2012

Invitation to Investor Luncheons with CEO: Melbourne 5 Dec and Sydney 7 Dec

November, 2011

iSonea Update on Commercialisation of Asthma Management Products

A $4.3M Rights Issue to Accelerate Development Milestone

New issue announcement, application for quotation of additional securities and agreement

Prospectus Announcement

Results of 2011 Annual General Meeting

iSonea granted voluntary suspension pending capital raising announcement

iSonea Announces Bank of New York Mellon Appointment

October, 2011

2011 Isonea Annual Financial Report

Annual Meeting Notice

CEO Mike Thomas Addresses Bergen Institutional
Investment

September, 2011

Letter to Shareholders on Bergen Announcement

iSonea Completes Agreement for $10.6 Million Investment

RB Milestone Group Commences coverage of iSonea Ltd.

RB Milestone Report on iSonea

August, 2011

iSonea Signs Memorandum of Understanding with Fortune 500 Healthcare Company

Letter to Shareholders: Update

Proactive Investors Australia: iSonea chief executive officer says company can lead a global revolution in asthma management

Click for Company stock information

Archive

Date Headline
Nov. 18 , 2010
Karmelsonix wins Frost & Sullivan New Product Innovation Award View
Nov. 17 , 2010
Karmelsonix highlights the clinical value proposition of its Products View
Nov. 11 , 2010
Karmelsonix signs agrements with distributors in France, Sweden, Finland, Denmark and Norway View
Nov. 9 , 2010
Shareholder Update - November 2010 View
Oct. 29 , 2010
Notice of Annual General Meeting 30th November, 2010 View
Oct. 29 , 2010
Highlights for the quarter ended 30th September, 2010 View
Oct. 28 , 2010
Karmelsonix appoints Mr. Bill Nicklin as Manufacturing Consultant View
Oct. 20 , 2010
Karmelsonix raises Approx. $2 M via issue of convertible notes View
Oct. 20 , 2010
Karmelsonix announces Board Restructure View
Sept. 2, , 2010
Proposed Management & Board Restructure View
July 19, 2010
FDA Grants Clearance for WHolter® Recorder View
June 28 , 2010
American Medical Association Approves CPT Codes for KSX WheezeRATE and CoughCOUNT Technology View
June 22 , 2010
KSX WHolter Service - New Revenue Model Launched View
June 15 , 2010
Karmelsonix Sales & Marketing Update View
April 20, 2010
Karmelsonix expands its Patent Portfolio in the US View
April 15, 2010
Karmelsonix signs distribution agreements in the United States View
April 8, 2010
European CE Mark granted to the company WHolter device View
Feb 16, 2010
Karmelsonix signs Agreement with second Distributor in India View
Feb 16, 2010
Key Appointments to Senior Sales & Marketing Team  
Feb 11, 2010
Appointment of New Board Directors View
Dec 18, 2009
Clinical Study Accepted for Publication in Asthma Journal View
Dec 10, 2009
KSX Announces Australian Pharmacy Distribution Agreement View
Dec 9, 2009
Successful Placement of Shares Raises Approx. $4.5m View
Dec 3, 2009
Karmelsonix secures marketing approval and first substantial order in India View
Nov 17, 2009
ACCP Applies for WheezeRate CPT Reimbursement Code View
Nov 16, 2009
Karmelsonix Expands European Distribution Channels View
Nov 12 2009
Result of Annual General Meeting View
Nov 10, 2009
Personal Wheezometer® adopted by ALMS Doctors View
Oct 13 2009
Notice of Annual General Meeting / Proxy Form View
Sep 27, 2009
Wheezometer® Granted FDA Clearance View
Sep 10, 2009
Karmelsonix Participation in ERS Congress - Brief Update View
Aug 10, 2009
Appointment of VP-Sales and Marketing View
Jul 30, 2009
KSX Technology Update and Commencement of Wheezometer® Sales View
Jul 23, 2009
Karmelsonix Expands Distribution Channels in Europe View
Jul 22, 2009
KSX Receives European CE Mark for its Cough Detector View
Jul 08, 2009
Distribution Agreement Signed with Medi-Point of South Korea View
Jun 22, 2009
KSX Launches its PulmoTrack Cough Counter Add On Technology View
May 28, 2009
KSX Receives TGA Approval for its Personal Wheezometer® View
May 18, 2009
Launch of Personal Wheezometer® at American Thoracic Society View
May 11, 2009
Grant of new UK Patent to determine airway patency View
May 07, 2009
First Sale of PulmoTrack into Sleep Laboratory Market View
Apr 20, 2009
Karmelsonix Receives Further Regulatory Clearance View
Apr 7, 2009
Karmelsonix award article View
Apr 7, 2009
Karmelsonix Receives 2009 European Frost and Sullivan Award View
Feb 23, 2009
Karmelsonix Raises New Capital View
Feb 10, 2009
ATS accepts KSX Abstracts for presentation at Annual Meeting View
Jan 13, 2009
Personal Wheezometer® receives regulatory approval in EU View
Dec 25, 2008
2008 Year-End Update View
Nov 17, 2008
Directorship View
Oct 31, 2008
Quarterly Report For The 3 Months Ended 30 September 2008 View
Oct 22, 2008
Notice of Annual General Meeting View
Oct 21, 2008
Grant of New Australian Patent View
Oct 16, 2008
Clinical and Marketing Update View
Oct 6, 2008
Change of Director’s Interest Notice View
Oct 3, 2008
New Issue Announcement, Application for Quotation of Additional Securities and Agreement View
Oct 2, 2008
Annual Financial Report For The Year Ended 30 June 2008 View
Sep 16, 2008
Notice of change of interests of substantial holder View
Sep 16, 2008
Change of Director’s Interest Notice View
Sep 16, 2008
Change of Director’s Interest Notice View
Sep 2, 2008
Change of Director’s Interest Notice View
Sep 2, 2008
Change of Director’s Interest Notice View
Aug, 29, 2008
Karmelsonix Limited, Appendix 4E Preliminary Final Report View
Aug 26, 2008
Appointment of US Marketing and Sales Director & Appointment of Asia Pacific Marketing Executive Director View
Aug 25, 2008
New Issue Announcement, Application for Quotation of Additional Securities and Agreement View
Aug 25, 2008
Karmelsonix Secures Committed Equity Facility Agreement With Trafalgar Capital Specialised Investment Fund For Up To $7.2 Million View
Aug 4, 2008
Notice of change of interests of substantial holder View
Aug 1, 2008
New Issue Announcement, Application for Quotation of Additional Securities and Agreement View
Jul 31, 2008
Quarterly Report for fhe 3 Months Ended 30 June 2008 View
Jul 4, 2008
Change of Director’s Interest Notice View
Jul 4, 2008
Change of Director’s Interest Notice View
Jul 4, 2008
New Issue Announcement, Application for Quotation of Additional Securities and Agreement View
Jul 4, 2008
Results of Option Exercise Program View
Jun 26, 2008
PulmoTrack® Sales to Pharmacy Group in Australia Commence View
Jun 26, 2008
Change of Director’s Interest Notice View
Jun 25, 2008
Successful Completion of Personal Wheezometer® Engineering Prototype View
Jun 22, 2008
New Issue Announcement, Application for Quotation of Additional Securities and Agreement View
Jun 18, 2008
US – Israel Binational R&D Foundation Approves Funding of Joint Venture WIM-GER™ Development View
Jun 17, 2008
Clinical Study Confirms Utility of Acoustic Transmission Technology in Assessing Asthma View
Jun 12, 2008
PulmoTrack starts selling in Europe, China, and Taiwan View
Jun 3, 2008
RM Wise, Research Report Available View
Jan 14, 2008
RM Reasearch Report View

 

© 2012 iSonea (formerly Karmelsonix) Ltd| Disclaimer, Terms and Conditions, Copyright and Intellectual Property.

BlackFin Processor
BlackFin® Processor
KarmelSonix ISO Certification
iSonea
ISO Certification 2003
US Food & Drug Administration

US Food & Drug Administration
Australian Government

Australian Government
Therapeutic Goods Administration


CE Certification

CE Certification